Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer

Marcus Beck,Dirk Böhmer,Daniel M. Aebersold,Clemens Albrecht,Michael Flentje,Ute Ganswindt,Stefan Höcht,Tobias Hölscher,Arndt-Christian Müller,Peter Niehoff,Michael Pinkawa,Felix Sedlmayer,Daniel Zips,Sebastian Zschaeck,Volker Budach,Thomas Wiegel,Pirus Ghadjar,
DOI: https://doi.org/10.1007/s00066-019-01553-3
2019-11-29
Strahlentherapie und Onkologie
Abstract:ObjectiveThis article aims to provide an overview of the role of combined radiation and androgen deprivation (ADT) therapy in patients with intermediate-risk prostate cancer.Materials and methodsThe current German, European, and NCCN (National Comprehensive Cancer Network) guidelines as well as relevant literature in the PubMed database which provide information on sub-classification within the intermediate-risk group and the use of ADT in terms of oncological outcome were reviewed.ResultsDifferent recommendations for risk-group assessment of patients with localized prostate cancer are available. Subdivision of intermediate risk into a favorable and an unfavorable group seems to be justified to allow for a more individualized therapy in a quite heterogenous group of patients. So far, multiple randomized trials have shown a benefit when radiation therapy (RT) is combined with ADT. The use of dose-escalated RT without ADT also appears to be an adequate therapy associated with a very low rate of cancer-specific deaths. Therefore, taking into account the increased rate of toxicity associated with ADT, dose-escalated RT alone might be justified, especially in favorable intermediate-risk patients.ConclusionDose-escalated RT alone appears to be an appropriate treatment in favorable intermediate-risk patients. Addition of short course ADT (4–6 months) might improve outcomes in unfavorable intermediate-risk patients.
oncology,radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?